2 results
Not approvedWill not start
The objective of the study is to compare the safety and efficacy of masitinib at 4.5 mg/kg/day or masitinib at 4.5 mg/kg/day with a dose escalation to 6 mg/kg/day after three month of treatment versus placebo in the treatment of patients with…
Approved WMOWill not start
To improve overall survival of patients with a early-stage high grade uterine leiomyosarcoma.